65,437 trials
Cerebral Palsy · Conditions Similar to Cerebral Palsy
Primary: Change in Child Participants' Understanding How to Use a Power Mobility Device Between Baseline and Immediately After the Conclusion of the Intervention Period at Week 3…
Locally Advanced Paraganglioma · Metastatic Adrenal Gland Pheochromocytoma · Metastatic Paraganglioma
Primary: Objective Response Rate — 25 percentage of participants
Gout
Primary: Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF) — 38.1; 73.6 percentage of participants — p=<0.001
Irritable Bowel Syndrome
Primary: Lactulose Mannitol Excretion — 512.5; 394.5; 456.8; 411 micrograms per ml
Flat Feet · High Arched Foot
Primary: Change From Baseline in Body's Postural Symmetry Index(SSIM Gray) at 2 Months — -0.031; 0.010 score on a scale
Pre-exposure Prophylaxis · HIV Infections
Primary: Number of Service-users Who Initiate PrEP Uptake Within the TB HIV Care Programme — 17949; 3091; 924; 925 Participants — p=0.707
Respiratory Syncytial Virus
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection — 689; 547 Participants
CMV · CMV Infection · Hematopoietic Cell Transplant
Primary: Clinically Significant CMV Viremia for Hematopoietic Cell Transplantation/HCT Participants in the Interventional Cohort Only — 5; 0; 31; 0 Participants
Mycobacterium Infections, Nontuberculous · Mycobacterium Abscessus Infection · Nontuberculous Mycobacterial Lung Disease
Primary: Percentage of Participants With Clinical Response on NTM Symptom Assessment Scale at Day 84 — 34.1; 20.0 Percentage of participants — p=0.2182
Coronary Artery Disease
Primary: Percentage of Participants With Reclassification of CAD Management, Assessed as the Therapeutic Recommendations Made Based on Review of Coronary CTA Alone Versus CTA +…
HIV-1-infection
Primary: Antiviral Activity at Week 48 of DTG+3TC Among ART-naïve HIV Patients With a CD4 Count ≤200 Cells/mm3. — 125; 62 Participants
COVID-19
Primary: Number of Participants With Adverse Events — 5; 9; 10; 8 Participants
Cervical Cancer
Primary: DLT Evaluation for Safety and Tolerability(Part A) — 0 participants
Asthma
Primary: Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 15 Minutes (AUC0-15 Min) Post-dose — 2.969; 2.970; 2.955…
Depressive Symptoms
Primary: Change in Engagement in Physical Activity — 318; 346 steps per day